Skip to content

A Community-based Prospective Cohort Study on Metabolic Dysfunction-Associated Fatty Liver Disease in Older Adults: From Metabolic Trajectories to Extrahepatic Outcomes

Study on the Construction of Disease Cohort for Fatty Liver in the Elderly and Its Prevention and Treatment Strategies

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07241195
Acronym
COMET cohort
Enrollment
20000
Registered
2025-11-21
Start date
2026-03-12
Completion date
2030-12-31
Last updated
2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

NAFLD and NASH, NAFLD Cirrhosis, NAFLD( Non-alcoholic Fatty Liver Disease )

Brief summary

To establish a cohort of elderly fatty liver disease based on the community medical examination population. Through the large-scale cohort study, the risk factors affecting fatty liver in the elderly will be explored in depth from the aspects of lifestyle, environment and genetics, the development pattern and mechanism of fatty liver in the elderly will be analysed, and the health risk assessment system and Chinese standard for fatty liver in the elderly covering cardiovascular risk, risk of hepatic fibrosis and risk of sarcopenia will be established, so as to provide the scientific basis for the precise intervention of fatty liver in the elderly in China.

Interventions

None listed

Sponsors

The Affiliated Hospital of Hangzhou Normal University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
65 Years to 100 Years
Healthy volunteers
Yes

Inclusion criteria

* ① Elderly people aged ≥65 years among permanent residents (living for more than 5 years) in the survey area; * Imaging diagnosis (ultrasound or FibroScan/FibroTouch) of fatty liver; -③ Voluntary participation in this study and signing an informed consent form.

Exclusion criteria

* ①Major disability, mental illness, major wasting disease, severe cardiac, pulmonary and renal insufficiency; * Patients with combined primary liver cancer or other types of cancer; -③Patients who have received liver transplant or other organ transplants.

Design outcomes

Primary

MeasureTime frame
Incidence of liver fibrosis2 years

Secondary

MeasureTime frame
Incidence of cardiovascular disease2 years
Incidence of sarcopenia2 years

Countries

China

Contacts

CONTACTWei Zhang, DR
zhangwei969696@163.com+8613567135527

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 2, 2026